SHORT REPORT

Reduced cerebral cortical but elevated striatal concentration of somatostatin-like immunoreactivity in dominantly inherited olivopontocerebellar atrophy

Stephen J Kish, Yves Robitaille, Munir El-Awar, Lawrence Schut, Linda DiStefano, Melvyn J Ball, Michael F Mazurek

Abstract
Somatostatin-like immunoreactivity (SLI) was measured in the brains of nine patients with dominantly inherited olivopontocerebellar atrophy (OPCA), who all had a marked deficit of the cholinergic marker cholineacetyltransferase (ChAT) in the cerebral cortex and striatum. Mean concentrations of SLI in OPCA were significantly reduced by 42-50% in parietal and occipital cortices and frontal cortical eye fields, but were normal in other cortical areas, including two subdivisions of the temporal cortex which showed marked depletions of both SLI and ChAT in Alzheimer's disease. This dissociation of SLI and ChAT indicates that a cortical cholinergic deficit does not invariably lead to reduction of somatostatin. In the caudate nucleus, the region of OPCA brain having the most severe ChAT deficit (~81%), SLI levels were significantly elevated by 46% and were negatively and significantly correlated with ChAT activities (r=-0.66). The SLI alterations could be due to abnormal somatostatin metabolism or release, or an increased number of somatostatin-containing neurons and could contribute to the brain dysfunction of OPCA.


Patients and methods
Necropsied brain was obtained from nine patients with OPCA and 10 control subjects dying without evidence of neurological or psychiatric disease who were matched with respect to age (OPCA mean 39 (SE 3); controls: 40 mean (SE 5) years; p > 0.05; Student's two tailed t test) and postmortem time (OPCA: 10 (2) hours; controls: 11 (2) hours; p > 0.05). At necropsy one half-brain was frozen at −80°C for biochemical investigation whereas the other half-brain was fixed in formalin for neuropathological analysis (YR, MB). The nine OPCA patients were from pedigrees S (n = 6), Se (n = 1), C (n = 1), and D (n = 1) in which at least three successive generations have been affected. We have previously reported a cerebral cortical/striatal ChAT deficit in the brains of five of the six pedigree S patients examined in the present study. All patients had severe lim...
ataxia and dysarthria and were either wheelchair-bound or bedridden. Formal neuropsychological testing had been conducted on three of the pedigree S patients.12 Neurological assessment of the other three pedigree S patients, and the two patients from pedigrees Se and C, did not reveal any clinically significant dementia. Moderate to severe dementia was observed only in the single patient from pedigree D, in which neuropathological analysis revealed moderate cerebral cortical neuronal loss (see below). Neuropathological analysis confirmed the diagnosis of OPCA with severe Purkinje cell loss in cerebellar cortex, and neuronal loss with gliosis in the pons and inferior olives. Microscopic analysis of the cerebral cortex (frontal, parietal, temporal, occipital) showed no evidence of neuronal cell loss or gliosis in six of the nine patients (pedigree S, n = 4; pedigree Se, n = 1; pedigree C, n = 1) with two patients (pedigree S) showing slight neuronal cell loss and gliosis in parietal cortex (other cerebral cortical areas within normal limits). The single patient from pedigree D showed moderate cerebral cortical neuronal loss with little gliosis affecting primarily the deeper cortical layers. The neuronal population of the striatum (caudate and putamen) was within normal limits in six of the nine patients whereas in three patients (pedigree S, n = 2; pedigree C, n = 1) minimal/mild neuronal cell loss could be observed; these changes were not associated with specific abnormalities on silver stains. No senile plaques or neurofibrillary tangles were observed in the brains of any of the OPCA patients. SLI was measured by radioimmunoassay as previously described.3 The assay recognises amino acids 6 to 10 of the tetradecapeptide somatostatin. Somatostatin 14 and 28 are recognised on an equimolar basis. ChAT activity was determined using the radiochemical procedure of Fonnum.13

Results

Compared with the controls, mean levels of SLI were significantly reduced (p < 0.05 or less, Student’s two tailed t test) by 42–58% in Brodmann areas 8 (frontal eye field), 7b (parietal cortex), and 18 (occipital cortex) but were normal in areas 6 (pre-motor cortex), 20 (inferior temporal gyrus), and 38 (temporal pole), and in the putamen (see Table). The 32% mean reduction of SLI in area 4 (pre-central gyrus) just missed statistical significance at the 0.05 level. SLI concentration, on average, was significantly elevated by 46% (p < 0.05) in the caudate nucleus of the OPCA patients. By comparison, mean ChAT activity was markedly and significantly (p < 0.001) reduced by 50 to 81% in all nine examined brain areas with the greatest reduction occurring in the caudate nucleus. In this OPCA group no statistically significant (p > 0.05) correlation was observed between SLI and ChAT levels in any of the seven cerebral cortical areas or in the putamen. In the caudate nucleus, however, a significant (p < 0.05) negative correlation (r = –0.66) was observed between SLI and ChAT values in the OPCA patients.

Discussion

Whereas the brain neuropathology of affected patients from the examined OPCA families has been generally assumed to be restricted primarily to the cerebellum and lower brain stem, our data show abnormal levels of SLI in OPCA cerebral cortex and striatum with a regional pattern differing from that reported for other brain neurodegenerative conditions. Our finding of decreased SLI in OPCA cerebral cortex can be compared with Alzheimer’s disease, in which a cortical SLI deficit is a feature of this condition, but in which, unlike OPCA, SLI levels are reduced by 42–58% in the temporal lobe4 and are normal in striatum.14 Increased striatal SLI, observed in our OPCA patients, is also found in Huntington’s disease,15 but in the latter condition none of the (24) cerebral cortical areas examined showed the decreased SLI we have observed in OPCA.

In cerebral cortex somatostatin-immunoactive neurons are found in a subpopulation of locally projecting neurons (cf Beal et al). The SLI deficit in OPCA cerebral cortex could be explained by loss of somatostatin-containing neurons. However, our preliminary observation16 that the SLI deficient areas of OPCA cerebral cortex contain normal concentration of neuropeptide Y (which, to a large extent is co-localised with somatostatin in human cerebral cortical neurons),17 argues against neuronal cell loss as an explanation for the reduced SLI and points towards a change in somatostatin release, metabolism, or prosomatostatin metabolism. This differs from Alzheimer’s disease cerebral cortex in which reduced levels of both SLI (see above) and neuropeptide Y18 are observed.

Unlike the cerebral cortex, mean SLI concentration in striatum (caudate) was actually elevated in the OPCA patients. Increased striatal levels of SLI are also observed in Huntington’s disease,15 which is associated with marked atrophy of the striatum. Since none of our OPCA patients had, upon gross inspection, striatal atrophy, the SLI elevation is unlikely to be consequent to any artefactual increase resulting from tissue shrinkage.

---

**Table:** Somatostatin-like immunoreactivity (SLI) and choline acetyltransferase (ChAT) in necropsied human brain: control vs dominantly inherited olivopontocerebellar atrophy (OPCA)

<table>
<thead>
<tr>
<th>Brain area</th>
<th>SLI</th>
<th>ChAT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>OPCA</td>
</tr>
<tr>
<td>4</td>
<td>28.9 (3.6)</td>
<td>19.7 (2.8)</td>
</tr>
<tr>
<td>6</td>
<td>25.5 (2.9)</td>
<td>21.6 (1.9)</td>
</tr>
<tr>
<td>7b</td>
<td>28.8 (2.1)</td>
<td>12.0 (1.9)**</td>
</tr>
<tr>
<td>8</td>
<td>31.1 (2.0)</td>
<td>18.1 (3.3)</td>
</tr>
<tr>
<td>18</td>
<td>29.7 (2.0)</td>
<td>14.5 (2.1)**</td>
</tr>
<tr>
<td>20</td>
<td>31.4 (3.9)</td>
<td>35.3 (6.6)</td>
</tr>
<tr>
<td>38</td>
<td>34.9 (5.3)</td>
<td>39.0 (5.5)</td>
</tr>
<tr>
<td>Caudate</td>
<td>34.4 (4.4)</td>
<td>50.2 (5.2)**</td>
</tr>
<tr>
<td>Putamen</td>
<td>44.2 (7.2)</td>
<td>60.1 (7.9)</td>
</tr>
</tbody>
</table>

Values (SLI, pg somatostatin-14/mg tissue; ChAT, pmol/mg protein/10 minutes) represent mean (SE) of nine patients with OPCA and 10 control subjects. Numbered brain areas are Brodmann cerebral cortical subdivisions. 

*p < 0.05, **p < 0.01, ***p < 0.001; Student’s two-tailed t test."
The regional patterns of the SLI and ChAT changes were dissimilar, the most striking difference being the temporal cortex, which consistently shows both ChAT and SLI loss in Alzheimer's disease, but which, in OPCA, shows only a cholinergic reduction. Our data indicate therefore that a loss of cholinergic innervation to cerebral cortex does not inevitably result in a cortical somatostatin deficit. SLI levels were elevated in the caudate nucleus, the region of OPCA brain found to have the most marked ChAT reduction. In striatum, somatostatin immunoreactivity is contained in medium sized aspyne neurons where it is co-localised with neuropeptide Y and NADPH diaphorase. This neuronal population is distinct from the large aspyne cholinergic interneuron of the striatum. Observation of a significant negative correlation between caudate SLI and ChAT levels suggests the interesting possibility that a primary loss or downregulation of striatal cholinergic neurons might result in nerve terminal sprouting or upregulated neuropeptide synthesis in the striatal somatostatinergic neurons.

The functional significance of the brain somatostatin changes in OPCA, as well in Alzheimer's disease, is uncertain. In Alzheimer's disease SLI has been observed in neuritic plaques in and in neurons containing neurofibrillary tangles, suggesting that this neuropeptide could play a role in the neurodegenerative process. However, senile plaques and neurofibrillary tangles were not observed in the brain of any of our (young, mean age 39 years) OPCA patients, indicating that formation of these brain pathological markers of neurodegeneration cannot be an invariable consequence of cortical somatostatin loss. The observations of a correlation between brain somatostatin levels in Alzheimer's disease and Parkinson's disease with dementia with a degree of cognitive impairment has also implied a role for somatostatin in cognition. However, in our study clinically significant dementia was observed only in the single patient from pedigree D, with pedigree S patients typically having only clinically mild frontol subcortical type cognitive deficits upon formal neuropsychological testing.

This suggests that a cerebral cortical somatostatin deficit of the magnitude and regional pattern observed in OPCA is not sufficient to produce a clinically disabling dementia, but could provide the basis for part of the mild cognitive dysfunction in this disorder. The experimental finding of increased striatal dopamine release in the rodent following local somatostatin administration suggests that somatostatin might play an important role in the control of dopamine release at nigrostriatal neuronal terminals; this observation may be related to our previous demonstration of increased dopamine turnover (elevated dopamine metabolite/neurotransmitter ratio) in striatum of OPCA patients. We conclude that abnormal somatostatin function in both cerebral cortex and striatum, as suggested by our data, could contribute to part of the brain dysfunction of OPCA.

This study was supported by the US NIMH (NTNDS no. 26034 to SK) and the Ontario Mental Health Foundation and Alzheimer Association of America (to MM). Drs Kish and Mazurek are career scientists of the Ontario Ministry of Health.

Presented in part at the 117th annual meeting of the American Neurological Association, October, 1992, Toronto, Canada.